GlassScriptPhysician profile
Susan Pasnick
NPI 1669671772
$1,566.66
in general payments reported to CMS, 2019-2025
13 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.31 · 2022: $224 · 2023: $140 · 2024: $539 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $88.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.38 |
| Education | $88.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $318.13 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $299.24 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Verona Pharma, INC. | $196.55 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $192.47 | 2022-2025 | Nucala, Trelegy Ellipta |
| Mylan Specialty L.P. | $186.19 | 2022-2024 | Yupelri |
| Genzyme Corporation | $76.57 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.35 | 2023-2025 | Glassia |
| Insmed, INC. | $65.99 | 2023-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.24 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $44.65 | 2024-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $25.00 | 2023 | Prolastin-C Liquid |
| Viatris Specialty LLC | $24.11 | 2025 | Yupelri |
| Electromed, INC. | $22.17 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Pasnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.